A leader in the world of cellular therapies.
Cook MyoSite® is a leader in the regenerative medicine industry by advancing our own personalized investigational cell therapy products toward the market through extensive clinical trial experience.
FDA Grants RMAT Designation to Cook MyoSite's AMDC-USR
Dec. 17, 2020 — Cook MyoSite today announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Cook MyoSite’s AMDC-USR investigational product for treatment of women with persistent or recurrent stress urinary incontinence (SUI) following surgical treatment.
Cook MyoSite creates specialized treatments for patients. These treatments use the patient’s own muscle cells in a unique procedure that begins and ends with the patient’s own body. Currently, this technology is being investigated in clinical trials and is not commercially available.